⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7988561 | 0.97 | CA12 (0.47) | — | |
| SCHEMBL15091 | 0.85 | CA12 (0.52) | — | |
| SCHEMBL7777517 | 0.84 | ALDH1A1 (0.41) | — | |
| SCHEMBL4396393 | 0.84 | CA12 (0.41) | — | |
| SCHEMBL28731355 | 0.82 | CA12 (0.44) | — | |
| SCHEMBL12918862 | 0.82 | CA12 (0.56) | — | |
| Hydrochloric Acid SCHEMBL473385 | 0.82 | CA12 (0.50) | — | |
| SCHEMBL31696969 | 0.82 | CA12 (0.50) | — | |
| Water SCHEMBL2217898 | 0.82 | CA12 (0.50) | — | |
| SCHEMBL3973874 | 0.82 | CA12 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7196 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970711-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-30 | — | — | US | claimed |
| EP-4314297-A1 | TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE | Specific Biologics Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| WO-2024013361-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | PROQR THERAPEUTICS II B.V. (NL) | 2024-01-18 | — | — | WO | claimed |
| CN-117083385-A | Targeting oncogenic mutations with double-cleaving endonucleases | 特定生物制品公司 | 2023-11-17 | — | — | CN | claimed |
| US-11795472-B2 | RNA-guided nucleic acid modifying enzymes and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-24 | — | — | US | claimed |
| WO-2023201203-A2 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-19 | — | — | WO | claimed |
| EP-4240839-A1 | GENE EDITING WITH A MODIFIED ENDONUCLEASE | Specific Biologics Inc. (CA) | 2023-09-13 | — | — | EP | claimed |
| CN-116669775-A | Gene editing with modified endonucleases | 特定生物制品公司 | 2023-08-29 | — | — | CN | claimed |
| WO-2023152371-A1 | GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA | PROQR THERAPEUTICS II B.V. (NL) | 2023-08-17 | — | — | WO | claimed |
| WO-2023107531-A2 | ANTISENSE OLIGONUCLEOTIDE DRUG TARGETS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-15 | — | — | WO | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | claimed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | claimed |
| US-20020049173-A1 | Alteration of cellular behavior by antisense modulation of mRNA processing | ISIS PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | claimed |
| WO-2001072765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| WO-2001052902-A1 | ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| US-6210892-B1 | HYBRIDIZING AN ANTISENSE COMPOUND HAVING A 2' SUGAR, MORPHOLINO, OR PEPTIDE NUCLEIC ACID MODIFICATION TO TARGET MESSENGER RNA TO CHANGE ITS PROCESSING INCLUDING SPLICING, POLYADENYLATION OR STABILITY | ISIS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | claimed |
| US-4917989-A | MULTILAYER; TRANSPARENT SUBSTRATE, DYE AND REFLECTOR | BASF AKTIENGESELLSCHAFT (DE) | 1990-04-17 | — | — | US | claimed |